Change in the Roche Board of Directors
Roche (OTCQX: RHHBY) announced the resignation of Julie Brown from its Board of Directors, effective immediately, as she has accepted a new management role at another pharmaceutical company. Brown, who served on the Board since March 2016 and chaired the Audit Committee, will be succeeded temporarily by Dr. Patrick Frost until the Annual General Meeting in March 2023. Roche Chairman Christoph Franz acknowledged Brown's significant contributions to the company, emphasizing her impact on Roche's success.
- Julie's Brown departure opens the opportunity for fresh leadership perspectives on the Board.
- Dr. Patrick Frost's interim leadership may ensure continuity in the Audit Committee's operations until the new chair is appointed.
- Loss of Julie Brown may create a gap in financial oversight given her critical role as Chairwoman of the Audit Committee.
- Potential concerns regarding continuity and experience during the interim period without a permanent Audit Committee chair.
Basel, 26 September 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Julie Brown has notified the Board that she will step down as a member of the Roche Board of Directors as she has accepted a management role at another pharmaceutical company. This change will be effective from today.
Ms. Brown was elected to the Board of Directors in March 2016 and has since been the Chairwoman of the Audit Committee. Dr. Patrick Frost will chair the Audit Committee on an interim basis until the Annual General Meeting in March 2023.
Roche Chairman Christoph Franz: "As a Board member and Chairwoman of the Audit Committee, Julie Brown has contributed significantly to Roche’s success. On behalf of the Board, I would like to express our sincere thanks for Julie’s commitment and contributions to Roche and wish her all the best for the future.”
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 61 687 41 47 | Nathalie Altermatt Phone: +41 61 687 43 05 |
| Karsten Kleine Phone: +41 61 682 28 31 | Nina Mählitz Phone: +41 79 327 54 74 |
| Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | Sileia Urech Phone: +41 79 935 81 48 |
Attachment
FAQ
What led to Julie Brown's resignation from Roche's Board of Directors?
Who will lead Roche's Audit Committee after Julie Brown's departure?
When did Julie Brown join Roche's Board of Directors?
What are the implications of Julie Brown's departure for Roche (RHHBY)?
How has Roche acknowledged Julie Brown's contributions?
